Cited by Is colchicine on its way to a place in the polypill for cardiovascular prevention?

Updates in Medical Management of Peripheral Artery Disease DOI

Adeel Ahmad,

Stanislav Henkin

Current Treatment Options in Cardiovascular Medicine, Journal Year: 2025, Volume and Issue: 27(1)

Published: Jan. 4, 2025

Language: Английский

Citations

Role of C-Reactive Protein as a Predictor of Early Revascularization and Mortality in Advanced Peripheral Arterial Disease DOI

Giuseppe Di Stolfo, Mario Mastroianno,

Michele Antonio Pacilli

et al.

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(3), P. 815 - 815

Published: Jan. 26, 2025

Background: Elevated high-sensitivity C-reactive protein (hsCRP) levels are associated with poor cardiovascular outcomes, particularly in patients advanced peripheral arterial disease (PAD). This study aimed to assess the impact of hsCRP on clinical characteristics and long-term outcomes a cohort PAD patients. Methods: A total 346 were enrolled stratified into two groups based their median level (Group 1: <0.32 mg/dL, Group 2: >0.32 mg/dL). The followed for mean 102.70 ± 44.13 months. Their characteristics, comorbidities, events, including myocardial and/or revascularization, ischemia, death, analyzed. evaluated composite endpoints: major adverse events (MACEs) (MAPEs). MACEs comprised fatal cerebral cardiac infarction, acute occlusion, reperfusion. MAPEs included carotid reperfusion, lower limb revascularization. Results: 2 had higher body mass index, waist circumference, waist–hip ratio compared those 1 (all p < 0.05). Inflammatory markers, fibrinogen erythrocyte sedimentation rate, significantly elevated (both 0.01). While overall incidence revascularization was similar between groups, these interventions occurred earlier (28.24 38.87 months vs. 67.04 49.97 months, = 0.004; HR: 2.015, 95% CI: 1.134–3.580, 0.017). comparable number, but (36.60 37.35 66.19 48.18 0.01; 1.99, 1.238–3.181, 0.004). Similarly, an onset (40.31 38.95 55.89 46.33 0.04; 1.62, 0.983–1.987, 0.062). 169 deaths recorded during follow-up. exhibited mortality rate (56% 42%, 0.01) trend (76.58 43.53 84.86 5.18 months), although this difference did not reach statistical significance (p 0.22). Conclusions: (>0.32 mg/dL) worse profile PAD. experienced MACEs, MAPEs. rates also higher, highlighting prognostic value population.

Language: Английский

Citations

Response to Comment on “Colchicine to prevent cardiovascular death after an acute myocardial infarction” DOI